Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial

被引：42
|
作者：
Schneider, LS [1 ]
Ismail, MS [1 ]
Dagerman, K [1 ]
Davis, S [1 ]
Olin, J [1 ]
McManus, D [1 ]
Pfeiffer, E [1 ]
Ryan, JM [1 ]
Sultzer, DL [1 ]
Tariot, PN [1 ]
机构：
[1] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA
来源：
SCHIZOPHRENIA BULLETIN | 2003年 / 29卷 / 01期
关键词：
Alzheimer's disease; atypical antipsychotic; psychosis; dementia; effectiveness;
D O I：
10.1093/oxfordjournals.schbul.a006991
中图分类号：
R749 [精神病学];
学科分类号：
100205 ;
摘要：
This article describes the development of the protocol for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Alzheimer's disease trial, which was developed in collaboration with the National Institute of Mental Health to assess the effectiveness of atypical antipsychotics for psychosis and/or agitation occurring in outpatients with Alzheimer's disease. The article provides a detailed description of the methodology used in the trial as well as the clinical outcomes and effectiveness measures incorporated into it, discussing the most salient issues encountered in developing the design of the trial, as well as the unique features of the trial.
引用
收藏
页码：57 / 72
页数：16
相关论文
共 50 条
  • [1] National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness- Alzheimer's disease (CATIE-AD): Baseline characteristics
    Ismail, M. Saleem
    Dagerman, Karen
    Tariot, Pierre N.
    Abbott, Shana
    Kavanagh, Sarah
    Schneider, Lon S.
    CURRENT ALZHEIMER RESEARCH, 2007, 4 (03) : 325 - 335
  • [2] Schizophrenia, Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) and number needed to treat: how can CATIE inform clinicians?
    Citrome, L.
    Stroup, T. Scott
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2006, 60 (08) : 933 - 940
  • [3] Association of 9-Hydroxy Risperidone Concentrations With Risk of Switching or Discontinuation in the Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease Trial
    Wessels, Alette M.
    Pollock, Bruce G.
    Anyama, Norbert G.
    Schneider, Lon S.
    Lieberman, Jeffrey A.
    Marder, Stephen R.
    Bies, Robert R.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (06) : 683 - 687
  • [4] The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: Schizophrenia trial design and protocol development
    Stroup, TS
    McEvoy, JP
    Swartz, MS
    Byerly, MJ
    Glick, ID
    Canive, JM
    McGee, MF
    Simpson, GM
    Stevens, MC
    Lieberman, JA
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 15 - 31
  • [5] The relationship between suicide and violence in schizophrenia: Analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset
    Witt, Katrina
    Hawton, Keith
    Fazel, Seena
    SCHIZOPHRENIA RESEARCH, 2014, 154 (1-3) : 61 - 67
  • [6] Statistical approaches to effectiveness measurement and outcome-driven re-randomizations in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) studies
    Davis, SM
    Koch, GG
    Davis, CE
    LaVange, LM
    SCHIZOPHRENIA BULLETIN, 2003, 29 (01) : 73 - 80
  • [7] Classification of Neuropsychiatric Symptoms Requiring Antipsychotic Treatment in Patients with Alzheimer's Disease: Analysis of the CATIE-AD Study
    Nagata, Tomoyuki
    Shinagawa, Shunichiro
    Nakajima, Shinichiro
    Plitman, Eric
    Mihashi, Yukiko
    Hayashi, Shogo
    Mimura, Masaru
    Nakayama, Kazuhiko
    JOURNAL OF ALZHEIMERS DISEASE, 2016, 50 (03) : 839 - 845
  • [8] Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study
    Nagata, Tomoyuki
    Nakajima, Shinichiro
    Shinagawa, Shunichiro
    Plitman, Eric
    Nakayama, Kazuhiko
    Graff-Guerrero, Ariel
    Mimura, Masaru
    JOURNAL OF ALZHEIMERS DISEASE, 2017, 60 (01) : 263 - 272
  • [9] The Antipsychotic Discontinuation in Alzheimer Disease Trial: Clinical Rationale and Study Design
    Devanand, D. P.
    Mintzer, Jacob
    Schultz, Susan
    Sultzer, David
    de la Pena, Danilo
    Gupta, Sanjay
    Colon, Sylvia
    Schimming, Corbett
    Pelton, Gregory H.
    Andrews, Howard
    Levin, Bruce
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 20 (04) : 362 - 373
  • [10] Alzheimer's Disease Clinical Trials: Changing the Paradigm
    Cummings, Jeffrey L.
    CURRENT PSYCHIATRY REPORTS, 2011, 13 (06) : 437 - 442
12345